Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435756 · ClinicalTrials.gov registry record
A Study of miRNA 371 in Patients With Germ Cell Tumors
A clinical trial of Germ Cell Tumor and Seminoma, sponsored by SWOG Cancer Research Network.
- Active
- Registry status
- 956
- Enrollment target
- 20
- Study locations
NCT04435756: Active study of Germ Cell Tumor and Seminoma, sponsored by SWOG Cancer Research Network.
NCT04435756 is a study of Germ Cell Tumor and Seminoma that is active but no longer recruiting, run by SWOG Cancer Research Network. The registered enrollment target is 956 participants, above the 297-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (222% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04435756, a study of Germ Cell Tumor and Seminoma, is active but no longer recruiting, sponsored by SWOG Cancer Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- 956 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Primary Outcome
Positive predictive value will be estimated using plasma miRNA 371 expression at relapse.
Conditions Studied
Interventions
- OTHER Biomarker Analysis
- PROCEDURE Blood Product Collection
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- PCR Oncology - Arroyo Grande
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Keck Medicine of USC Buena Park - Buena Park
- Epic Care-Dublin - Dublin
- Kaiser Permanente Dublin - Dublin
- Bay Area Breast Surgeons Inc - Emeryville
- Epic Care Partners in Cancer Care - Emeryville
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Kingman Regional Medical Center - Kingman
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2028-01-01 |
What the registry record for NCT04435756 still lists
NCT04435756 is an observational study that tracks outcomes without assigning an intervention. The registered 956 participants enrollment target is mid-sized for trials with a published cap, above the 297-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (222% higher).
The record links to 7 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 2 interventions - of which Biomarker Analysis is the first listed.
NCT04435756 names 20 study sites across 3 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04435756 about?
NCT04435756 is a clinical study titled "A Study of miRNA 371 in Patients With Germ Cell Tumors". This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back...
What is the current status of trial NCT04435756?
This trial is currently active not recruiting. The enrollment target is 956 participants. The study started on 2020-07-28. Estimated completion is 2028-01-01.
What conditions does trial NCT04435756 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Seminoma, Metachronous Malignant Neoplasm, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8.
What interventions are being tested in trial NCT04435756?
The interventions under investigation include: Biomarker Analysis (OTHER), Blood Product Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04435756?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04435756 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04435756's enrollment target sits among peer trials
956 4th of 19 higher than 16 of 19 other Germ Cell Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Germ Cell Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06225596 · 956 participants · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- NCT06259669 · 958 participants
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI